You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
A Systematic Review of Seizure-Freedom Rates in Patients With Benign Epilepsy of Childhood With Centrotemporal Spikes Receiving Antiepileptic Drugs
Published in:
Clinical Neuropharmacology, 44 (2021) 2, Seite 39-46
Language:
English
DOI:
10.1097/wnf.0000000000000435
ISSN:
1537-162X;
0362-5664
Origination:
Footnote:
Description:
<jats:sec><jats:title>Objectives</jats:title><jats:p>The objective of this study was to evaluate seizure remission rates in patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) receiving antiepileptic drugs.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>PubMed and Web of Science were searched for studies on pharmacotherapy in patients with BECTS using free search terms or Medical Subject Headings. Only studies that used seizure-freedom rates as an indicator for pharmaceutical efficacy were considered. Different antiepileptic drugs were compared using the Fisher exact test for seizure-freedom rates.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 19 studies were included, 6 of them being randomized controlled trials. The randomized controlled trials included a total of 308 patients and covered sulthiame (n = 52), topiramate (n = 45), levetiracetam (n = 43), oxcarbazepine (n = 31), carbamazepine (n = 68), and clobazam (n = 18) as well as placebo (n = 35) and untreated control groups (n = 16). Treatment success rates were significantly higher in those children treated with sulthiame, levetiracetam, and clobazam compared with the children treated with carbamazepine, oxcarbazepine, or topiramate.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The available literature suggests the use of sulthiame, levetiracetam, or clobazam as first-line agents for the treatment of BECTS.</jats:p></jats:sec>